In a disease where hope has been scarce for decades, Belgian biotech Bioxodes is rewriting the rules of stroke treatment. Join your host Mike Ward in conversation with CEO Marc Dechamps as he reveals how his team transformed an unlikely discovery from tick saliva into BIOX-101, a first-in-class candidate therapeutic that could revolutionize care for intracerebral hemorrhage (ICH) patients.
With no approved treatments available for ICH, a devastating condition that claims nearly 50% of patients within 30 days, Bioxodes' groundbreaking approach tackles both the inflammation and clotting that drive secondary brain damage, without increasing bleeding risk. Fresh from announcing their breakthrough Phase 2a trial results, where all treated patients experienced reduced brain bleeding and no deaths occurred over eight months of follow-up, Dechamps shares the remarkable journey from laboratory discovery to potential life-saving medicine.
Discover how millions of years of tick evolution led to this medical breakthrough, why traditional stroke treatments fall short in hemorrhagic cases, and what the promising clinical data means for the 3 million worldwide who suffer ICH annually.
As Bioxodes prepares to launch its €70 million Series B funding round and advance toward a potentially registrational Phase 2b trial, Dechamps reveals the challenges of developing treatments for neglected diseases and his vision for expanding this tick-derived platform to tackle broader thrombo-inflammatory conditions.
This episode offers exclusive insights into one of biotech's most compelling David-versus-Goliath stories, where innovative science meets urgent medical need in the race to bring hope to stroke patients who have had none.
Listen now: BioBiz Buzz Podcast featuring Bioxodes